A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib on Rosuvastatin or Metformin.

The secondary objective of the study was to assess the safety of Apatinib alone or Rosuvastatin/Metformin alone or concomitant medication.
Solid Tumor, Adult
DRUG: Apatinib in arm1|DRUG: Rosuvastatin|DRUG: Apatinib in arm2|DRUG: Metformin
Maximum Observed Plasma Concentration (Cmax), The Cmax is the maximum observed concentration, Up to Day 10|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]), The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time., Up to Day 10|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]), The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, Up to Day 10
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, An adverse event is any untoward medical occurrence in a patient or clinical study participant criteria, through study completion, an average of 35 or 37 days in two groups.
The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib on Rosuvastatin or Metformin.

The secondary objective of the study was to assess the safety of Apatinib alone or Rosuvastatin/Metformin alone or concomitant medication.